Bimatoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Bimatoprost: From Eyelash Hypotrichosis / Ocular Hypotension to Alopecia (Hair Loss)
One-Sentence Summary
Bimatoprost is a prostamide (prostaglandin F2α analog) best known clinically for treating ocular hypertension/glaucoma and for its FDA-approved use in eyelash hypotrichosis (Latisse). Among 10 TxGNN-predicted indications in this evidence pack, most (7 of 10) are flagged by the model's own rationale as knowledge-graph noise with no mechanistic or clinical support. The one candidate with genuine biological plausibility and substantial clinical-trial backing is Alopecia, supported by 11 clinical trials (4 rated Grade A) and 20 publications, including a completed Phase 2 program in both male androgenetic alopecia and female pattern hair loss.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No Norway/Taiwan license data on file (drug not marketed). Publicly known original indications: ocular hypertension/open-angle glaucoma and eyelash hypotrichosis |
| Predicted New Indication | Alopecia |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack (MOA field marked as Data Gap). Based on known pharmacology, bimatoprost is a synthetic prostamide analog that binds prostamide/prostanoid receptors on the hair follicle and dermal papilla, prolonging the anagen (growth) phase and increasing follicle density. This mechanism is already clinically validated: bimatoprost 0.03% ophthalmic solution is FDA-approved (Latisse) specifically for eyelash hypotrichosis, meaning its hair-growth-promoting effect is not a theoretical extrapolation but an established, approved pharmacological action.
The step from eyelash hypotrichosis to scalp alopecia (androgenetic alopecia, female pattern hair loss) is a logical mechanistic extension — both involve the same follicular growth-cycle biology, differing mainly in follicle type and androgen sensitivity. This is reflected in the underlying rationale data: multiple completed Phase 2 trials directly tested bimatoprost solution against vehicle and active comparators (minoxidil) in men and women with pattern hair loss, and a Phase 4 trial confirmed efficacy/safety in a related eyelash-loss population.
It is worth noting that of the 10 TxGNN-ranked candidates in this pack, most (e.g., periodontal malformation syndromes, Dandy-Walker malformation, pulmonary arteriovenous malformation, Ambras hypertrichosis) show mechanistic directions that are absent, unrelated, or even contradictory to bimatoprost's known pharmacology, and carry no supporting trials or literature — these are assessed as Hold/model noise. Alopecia is the only candidate that combines high TxGNN score, coherent mechanism, and a substantial, largely completed clinical trial base.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01325350 | Phase 2 | Completed | 306 | Bimatoprost solution vs. vehicle and OTC minoxidil 2% in women with female pattern hair loss |
| NCT01023841 | Phase 4 | Completed | 71 | Bimatoprost 0.03% vs. vehicle for eyelash loss/hypotrichosis in children |
| NCT01904721 | Phase 2 | Completed | 244 | Safety and efficacy of bimatoprost in men with androgenic alopecia (AGA) |
| NCT01325337 | Phase 2 | Completed | 307 | Bimatoprost solution vs. vehicle and OTC minoxidil 5% in men with androgenic alopecia |
| NCT01189279 | Phase 1 | Completed | 42 | Safety, tolerability, and PK of a new bimatoprost formulation in alopecia patients |
| NCT02170662 | Phase 2 | Completed | 33 | Effect of topical bimatoprost solution on androgen-dependent scalp hair follicles |
| NCT02848300 | Phase 1 | Completed | 11 | Local skin pharmacokinetics and tolerability of bimatoprost applied to scalp in AGA |
| NCT05600673 | Phase 1/2 | Completed | 30 | Combined CO2 fractional laser plus bimatoprost 0.03% for alopecia areata |
| NCT00187577 | NA | Completed | 14 | Latanoprost vs. bimatoprost ophthalmic solutions for eyelash regrowth in alopecia areata |
| NCT02676310 | Phase 1 | Terminated | 53 | Dose-escalation safety, tolerability, and PK study of bimatoprost in men with AGA |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40252129 | 2025 | RCT | Archives of Dermatological Research | CO2 fractional laser combined with bimatoprost enhances hair regrowth in alopecia areata |
| 29863806 | 2018 | Guideline | The Journal of Dermatology | Japanese clinical guideline for male- and female-pattern hair loss diagnosis and treatment |
| 28264599 | 2017 | Review | Expert Opinion on Investigational Drugs | Overview of bimatoprost for eyelash, eyebrow, and scalp alopecia |
| 37185388 | 2023 | Review | Current Oncology | Prevention and treatment options for chemotherapy-induced alopecia |
| 32250713 | 2022 | Review/Network Meta-analysis | The Journal of Dermatological Treatment | Comparative efficacy of non-surgical AGA treatments |
| 32642317 | 2020 | Review | Dermatology Practical & Conceptual | Prevention and treatment of chemotherapy-induced alopecia |
| 35278027 | 2022 | Cohort (open-label) | Dermatologic Therapy | Topical bimatoprost for eyelash loss in alopecia totalis/universalis |
| 35040730 | 2022 | Preclinical | Drug Delivery | Enhanced-penetration topical bimatoprost formulation with in vivo hair regrowth efficacy in AGA |
| 34304865 | 2021 | Review | Bulletin du Cancer | Alopecia and cancer: pathophysiology and clinical management |
| 38577618 | 2024 | Preclinical | International Journal of Pharmaceutics: X | Spanlastic nanogel delivery of bimatoprost for AGA, improved cutaneous deposition |
Norway Market Information
Bimatoprost currently has no marketing authorization on file for this evaluation (market_status: Not Marketed, total_licenses: 0). No license records are available to summarize.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Alopecia is supported by an L2 evidence level — multiple completed Phase 2 trials (n=244–307) directly comparing bimatoprost to vehicle/minoxidil in androgenetic and female pattern hair loss, plus an already-approved related indication (eyelash hypotrichosis) sharing the same growth-cycle mechanism. This is far stronger than the other 9 TxGNN candidates in this pack, most of which lack any supporting evidence and were assessed as Hold due to implausible or contradictory mechanisms.
To proceed, the following is needed:
- TFDA/Norway package insert warnings and contraindications (currently blocking safety pre-screening, DG001)
- Confirmed mechanism-of-action data from DrugBank or primary literature (DG002)
- A formal Norway/local market authorization pathway assessment, since the product is not currently marketed
- If pursuing broader alopecia subtypes, separate evaluation of lower-evidence related candidates (diffuse alopecia areata, genetic alopecia, hypotrichosis simplex of the scalp — all L4, flagged as Research Question) as exploratory extensions rather than primary indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.